Key points are not available for this paper at this time.
This study shows Class I evidence that weekly subcutaneous etanercept is well tolerated in Alzheimer disease dementia.
Butchart et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: